Drug Trial Radar · NCT01974323
Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris
Last checked: Nov 19, 2026Latest source record: Oct 9, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,238
Actual
Start
Nov 2013
Primary completion
Oct 2014
Study completion Oct 2014
Sponsor
- Lead sponsor
- Almirall, S.A.Industry
- Sponsor type
- Industry
- Collaborators
- Allergan
- First posted
- Nov 1, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess the safety and efficacy of dapsone gel versus vehicle control in patients with acne vulgaris.
Conditions
- Acne Vulgaris
Interventions
Dapsone GelDrug
Dapsone gel applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
Dapsone Gel VehicleDrug
Dapsone gel vehicle applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Patients With a Score of 0 (None) or 1 (Minimal) on the 5-point Global Acne Assessment Score (GAAS)Time frame: Week 12
- Change From Baseline in Inflammatory Facial Lesion CountsTime frame: Baseline, Week 12
- Change From Baseline in Noninflammatory Facial Lesion CountsTime frame: Baseline, Week 12
Locations
3 sites in 2 countries. Site status is shown where the registry gives one.
Site not named
Beverly Hills, California
Site not named
Aventura, Florida
Site not named
Windsor, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.